Skip to main content

TG Therapeutics, Inc.

corporate_fare Company Profile

TG Therapeutics, Inc.

TGTX·NASDAQ·Life Sciences·CIK 0001001316

TG Therapeutics is a fully integrated, commercial-stage biotechnology company that acquires, develops, and sells new treatments for B-cell diseases. The company has a research pipeline and has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BRIUMVI has also been approved by several regulatory agencies outside the U.S. for adult RMS patients with active disease, defined by clinical or imaging features. The company also assesses complementary products, technologies, and companies for in-licensing, partnerships, acquisitions, and investment. In December 2022, BRIUMVI received FDA approval based on data from the ULTIMATE I & II Phase 3 trials, which showed it was superior to teriflunomide in significantly reducing the annualized relapse rate (ARR), the number of T1 Gd-enhancing lesions, and the number of new or enlarging T2 lesions. These trial results were published in August 2022. TG Therapeutics commercially launched BRIUMVI in the U.S. in January 2023. In August 2023, the company entered into a commercialization agreement with Neuraxpharm Pharmaceuticals, S.L. BRIUMVI is an anti-CD20 monoclonal antibody administered to adults with RMS via a one-hour infusion every 24 weeks after the initial dose.

TG Therapeutics, Inc. (NASDAQ:TGTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for TGTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • TG Therapeutics Secures $500M Non-Dilutive Capital, Boosts Share Buyback to $300M
  • BRIUMVI Post-Hoc Analysis Reveals Significant Efficacy in Highly Active MS Patients
  • TG Therapeutics Reports Record 2025 Revenue & Net Income, Driven by BRIUMVI Sales and Significant Tax Benefit
  • TG Therapeutics Reports Strong 2025 Results, Raises 2026 Revenue Guidance to $875-$900M, and Authorizes New $100M Buyback
  • TG Therapeutics Reports Strong 2025 BRIUMVI Revenue, Issues Bullish 2026 Guidance, and Outlines Key Pipeline Milestones

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$616.29M
Net Income
$447.18M
Diluted EPS
$2.77
Op. Cash Flow
-$24.77M
Free Cash Flow
-$24.99M
Gross Profit
$515.57M
Operating Income
$123.32M
Cash & Equivalents
$79.15M
Total Debt
$245.65M
Debt / Equity
0.38×
Net Margin
72.6%
Shares Outstanding
155.31M sh
Source: 10-K · filed 2026-02-27 · accession 0001437749-26-006133
$63.21 -0.21% today
52-week range · as of 2026-11-09 $26.76 – $63.6
Market cap
$9.57B
Volume
2.1M (1.1× avg)
3-mo avg 1.9M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TGTX - Filings & News (Page 2)

TGTX
Mar 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.18
Real-time Price: $63.21 info
Change: +$33.03 (+109%) info
Market Cap: $9.574B info
TGTX
Mar 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $28.50
Real-time Price: $63.21 info
Change: +$34.71 (+122%) info
Market Cap: $9.574B info
TGTX
Feb 27, 2026, 5:05 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $29.70
Real-time Price: $63.21 info
Change: +$33.51 (+113%) info
Market Cap: $9.574B info
TGTX
Feb 26, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.61
Real-time Price: $63.21 info
Change: +$35.60 (+129%) info
Market Cap: $9.574B info
TGTX
Jan 13, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $29.82
Real-time Price: $63.21 info
Change: +$33.39 (+112%) info
Market Cap: $9.574B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets